Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
Yokoyama S, Higashi M, Kitamoto S, Oeldorf M, Knippschild U, Kornmann M, Maemura K, Kurahara H, Wiest E, Hamada T, Kitazono I, Goto Y, Tasaki T, Hiraki T, Hatanaka K, Mataki Y, Taguchi H, Hashimoto S, Batra SK, Tanimoto A, Yonezawa S, Hollingsworth MA.
Yokoyama S, et al. Among authors: hiraki t.
Oncotarget. 2016 Jul 5;7(27):42553-42565. doi: 10.18632/oncotarget.9924.
Oncotarget. 2016.
PMID: 27283771
Free PMC article.